Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Fig. 4

Patients harboring rare EGFR 19delins mutation obtained similar survival benefits from first-generation EGFR TKIs to those with EGFR 19del mutation. Kaplan-Meier curves were drawn for comparing the PFS between patients with EGFR 19delins and EGFR 19del (A), PFS among patients with different variants in EGFR 19delins cohort (B and C), and PFS between patients receiving different EGFR TKIs in EGFR 19delins cohort (D)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us